Journal: Redox Biology
Article Title: p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer
doi: 10.1016/j.redox.2026.104043
Figure Lengend Snippet: FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
Article Snippet: Nutlin-3, Cisplatin, 5-fluorouracil (5-FU), actinomycin D (Act.D), Etoposide, Alrizomadlin (APG-115), Olaparib, MG132, Liproxstatin-1 (Lipro-1), Ferrostatin-1 (Ferro-1), RSL3, Z-VAD-FMK, Chloroquine (CQ), and Oxaliplatin (Oxa) were purchased from MedChemExpress (Shanghai, China), Erastin and Arachidonic acid (AA) were purchased from Selleck (Shanghai, China).
Techniques: Standard Deviation, Expressing, Transfection, Luciferase, Reporter Assay, Activation Assay, ChIP-qPCR
